Pharvaris publishes Frontiers in Immunology study shaping Phase 3 CREAATE endpoints for acquired angioedema drug deucrictibant

Pharvaris reported publication of qualitative study results in Frontiers in Immunology on disease burden in acquired angioedema due to C1 inhibitor deficiency.

The findings highlighted frequent misdiagnosis, emergency care, painful attacks, major disruption to daily functioning, and patients relying on off-label treatments.

The work supported the use of established patient-reported outcomes as meaningful trial endpoints, helping define what patients consider improvement.

Results have already been presented via publication, shaping the design and endpoint selection for the ongoing Phase 3 CREAATE trial of deucrictibant.

Pharvaris positioned the study as a step toward patient-centered evidence in a condition with no approved preventive or on-demand therapies.